1stOncology™: Cancer Intelligence Service – Page 1139 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CoRegen, Inc. Closes More Than $93 Million Financing

On July 09, 2025 CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, reported the close of a $93,390,000 million financing. The proceeds from this round will be used to advance CoRegen’s chemistry, manufacturing, and controls (CMC) development, initiate a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program in patients with various solid-tumor types in the first half of 2026 and expand its leadership team with key hires to drive execution and support the company’s growth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The financing was accomplished under a private placement with a select number of investors. This funding builds upon CoRegen’s prior $28 million raise in early 2024, which supported the acquisition of an exclusive license from Baylor College of Medicine to sponsor the development of its innovative gene regulatory platform.

"We are delighted to have the support of our investors during this pivotal time of growth for the company," said Suneet Varma, CoRegen’s newly appointed Chairman. "This year marks a watershed moment as we build upon the tremendous scientific progress made by Dr. Bert O’Malley and his team at the Baylor College of Medicine. As we prepare to enter the clinic, we are motivated by the belief we have a potentially paradigm-shifting solution in our master gene regulatory platform for patients with some of the most difficult-to-treat solid-tumor cancers, including but not limited to triple negative breast cancer and glioblastoma, for which research to date hasn’t yet moved the needle in a meaningful way in many years. We believe our technology, a type of adoptive cell therapy (ACT), may provide a novel approach for unleashing the healing power of the immune system to eradicate additional forms of cancer."

CoRegen’s platform is based on the groundbreaking work on SRCs (steroid receptor coactivators) in the lab of Bert O’Malley, M.D., Chancellor at the Baylor College of Medicine, who is considered the "Father of Molecular Endocrinology." SRC-3 is overexpressed in most human cancers, and Treg cells’ cancer protection activity is dependent on SRC-3 in this critical immune cell type. Building on this work, CoRegen has carefully engineered cells where SRC-3 is knocked out through application of its proprietary platform, therefore allowing for the targeting of a broad network of immune checkpoint genes for a superior anti-tumor effect. These SRC genes, discovered 30 years ago by Dr. O’Malley, can regulate a wide number of genes in the body, making them an ideal master on-off switch for either stimulating or suppressing gene expression.

(Press release, CoRegen, JUL 9, 2025, View Source [SID1234663767])

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

On July 9, 2025 LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, reported that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE’s ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal cancers (View Source) (Press release, Lixte Biotechnology, JUL 9, 2025, View Source [SID1234654349]).

A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint blockade therapy (clinicaltrials.gov identifier: NCT03026062). The ;study showed that patients having tumors with inactivating mutations in PPP2R1A – the major scaffold subunit of protein phosphatase 2A (PP2A) – had significantly better overall survival, compared with patients who did not have this mutation in their tumors.

Inactivating mutations in PPP2R1A are known to reduce the enzymatic activity of PP2A, which is the target of LIXTE’s lead compound LB-100. Tumors with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is known to be associated with improved immune checkpoint responses.

LIXTE is currently investigating the activity of LB-100 in combination with checkpoint immunotherapy in two clinical trials. The first is enrolling patients with OCCC, led by Dr. Jazaeri at MD Anderson Cancer Center, and also is open at Northwester University. In this trial, LIXTE is collaborating with GSK to test LB-100 in combination with dostarlimab (anti PD1). In the second trial, at the Netherlands Cancer Institute, LIXTE is collaborating with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients.

"Not only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation of this biomarker with survival benefit in other cancer types," said Dr. Jazaeri, who was co-senior author of the Nature article. "Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson."

Bas van der Baan, LIXTE’s Chief Scientific Officer, added, "This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year."

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Metastatic Breast Cancer Study

On July 9, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company’s personalized off the shelf immunotherapy (Press release, BriaCell Therapeutics, JUL 9, 2025, View Source [SID1234654346]).

BriaCell’s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis following four doses of BriaCell’s Bria-OTS monotherapy. The complete response was first observed at two months ( previously reported ) and confirmed at four ( previously reported ) and now six months. The patient has been dosed with 12 cycles of Bria-OTS to date.

"These results represent an exciting clinical milestone in the Bria-OTS program," stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study. "We are seeing strong single agent activity in a very challenging population and are eager to explore this approach across more patient subtypes and tumors."

"We are highly encouraged by this remarkable and durable clinical response, especially at the lowest dose level," added Dr. William V. Williams, BriaCell’s President and CEO. "This data underscores the therapeutic potential of our Bria-OTS platform, and we look forward to further evaluating it in combination with a checkpoint inhibitor to improve outcomes in patients with advanced breast cancer."

About Bria-OTS

Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell’s lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673 ) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and check point inhibition combination dose expansion cohorts. The Company recently progressed into the dose expansion phase.

FULL-YEAR FINANCIAL REPORT 2024

On July 9, 2025 Valerio Therapeutics reported its full year results (Press release, Valerio Therapeutics, JUL 9, 2025, View Source [SID1234654342]).

Radiant Biotherapeutics Appoints Deborah Geraghty, Ph.D., as President and Chief Executive Officer

On July 9, 2025 Radiant Biotherapeutics, a biotechnology company committed to advancing and delivering transformative MULTi-specific, multi-Affinity antiBODY (Multabody) therapeutics for patients with cancer and autoimmune diseases, reported the appointments of seasoned biotechnology executive Deborah Geraghty, Ph.D., as President and Chief Executive Officer, entrepreneur and venture investor Stefan Larson, Ph.D., as Chair of the Board of Directors, and distinguished physician-scientist Ingmar Bruns, M.D., Ph.D., as Board Member (Press release, Radiant Biotherapeutics, JUL 9, 2025, View Source [SID1234654320]).

Stefan Larson, Ph.D., incoming Chair of Radiant Biotherapeutics, commented: "Dr. Geraghty brings a proven track record of building and transforming innovative biotechnology companies and we are delighted to welcome her to Radiant. Her deep industry expertise and strategic vision make her the ideal CEO to lead Radiant through this next phase of growth as we advance our lead clinical candidate, a 4-1BB agonist, toward clinical trials and expand our preclinical pipeline more broadly across oncology and autoimmunity."

Dion Madsen, outgoing Chair and continuing Board Member of Radiant Biotherapeutics, noted: "We are thrilled to welcome Stefan and Ingmar to our board of directors as we move towards the clinic with our lead program. The addition of Dr. Larson and Dr. Bruns brings relevant expertise necessary for us to successfully deliver our next-generation biologics to patients with cancer and autoimmune diseases. We appreciate Arthur Fratamico’s leadership and foundational contributions to the Company during his four-year tenure as CEO."

These appointments follow the company’s successful $35 million Series A financing and build upon the recent progress by founding Chief Scientific Officer, Jo Hulme, Ph.D. Multabody, Radiant’s proprietary, best-in-class antibody platform, leverages remarkable avidity on intended targets while exploiting specificity to address multiple epitopes and different disease-modifying proteins. Antibodies developed using the Radiant platform are designed to deliver exceptional potency against both solid tumors and blood cancers, immunological targets, and infectious disease pathogens.

Deborah Geraghty, Ph.D., President and Chief Executive Officer of Radiant Biotherapeutics, added: "What drew me to this role are the compelling preclinical data based on the strong scientific foundation of Radiant’s unique biologic platform and the team that shepherded it this far. The opportunity to drive innovation for patients and realize the value of its application for devastating cancer and autoimmune diseases is energizing and I look forward to bringing these breakthrough therapies into the clinic."

Deborah Geraghty, Ph.D., is an accomplished life sciences executive with over 20 years of experience having built a strong foundation of financial, operational and strategic expertise throughout her career leading innovative biopharmaceutical companies. She most recently served as President and CEO of Anokion SA, a Phase 2 clinical-stage Swiss biotech company focused on developing a new class of immune tolerance therapies for autoimmune disease. Prior to that, she was Senior Vice President of Corporate Strategy at Dimension Therapeutics, where she led Dimension’s initial public offering and subsequent acquisition by Ultragenyx in 2017. Her earlier roles include co-founder and Vice President of Project and Portfolio Development at Cydan Development and leadership positions at Aileron Therapeutics as Head of Portfolio Advancement and Infinity Pharmaceuticals as Director of New Product Marketing. Dr. Geraghty holds a B.S. in Biology from Union College, an MBA from Boston College, and a Ph.D. in Molecular Biology from the University of Vermont.

Stefan Larson, Ph.D., is a Venture Partner at Sectoral Asset Management and serves on several biotech boards including Prilenia Therapeutics, Apnimed, and Stratus Therapeutics. He previously was an Entrepreneur-in-Residence and later Venture Partner at Versant Ventures, where he led the establishment of their Toronto-based Discovery Engine and served as founding CEO of Northern Biologics. Dr. Larson co-founded two medical device companies, Perimeter Medical Imaging and Tornado Spectral Systems, and began his career at McKinsey & Company. He holds a B.Sc. in Biology from McGill University, an M.Sc. in Molecular and Medical Genetics from University of Toronto, and a Ph.D. in Biophysics from Stanford University.

Ingmar Bruns, M.D., Ph.D., is a physician-scientist with two decades of hematology and oncology expertise who currently serves as Chief Medical Officer of Zentalis. He previously served as Chief Medical Officer of Trillium Therapeutics through its acquisition by Pfizer, then held senior clinical development roles at Pfizer, including head of the hematologic malignancies franchise. Earlier positions include Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals and clinical development leadership at Bayer Pharmaceuticals. Dr. Bruns served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf and Albert Einstein College of Medicine. He has authored over 50 publications in leading journals and holds an M.D. and Ph.D. from the University of Lubeck in Germany.